Ocular Therapeutix, Inc. (OCUL): A Bull Case Theory [Yahoo! Finance]
Ocular Therapeutix, Inc. (OCUL)
Last ocular therapeutix, inc. earnings: 3/12 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ocutx.com
Company Research
Source: Yahoo! Finance
Ocular Therapeutix, Inc.'s share was trading at $8.88 as of February 16th. Hesai (HSAI) Climbs 11% on Rating, PT Upgrade; Points to 16% Upside Potential l i g h t p o e t/Shutterstock.com Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. OCUL has emerged at the center of renewed acquisition speculation as rumors suggest that Sanofi may be preparing a significantly higher bid of around $30 per share, up from the $16 offer rejected last year when OCUL traded near $10.50. The urgency for Sanofi is clear: Dupixent, its blockbuster biologic, faces loss of exclusivity in 2031, and with expected 2025 revenues of approximately $18 billion, the company is seeking a new growth driver. Ocular's pipeline, particularly its wet AMD and diabetic eye disease programs, offers Sanofi exposure to a $15
Show less
Read more
Impact Snapshot
Event Time:
OCUL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OCUL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OCUL alerts
High impacting Ocular Therapeutix, Inc. news events
Weekly update
A roundup of the hottest topics
OCUL
News
- Ocular Therapeutix, Inc. (OCUL) Discusses Phase III SOL-1 Data Highlighting Transformative Durability in Wet AMD Transcript [Seeking Alpha]Seeking Alpha
- Ocular Therapeutix (OCUL) had its "outperform" rating reaffirmed by William Blair.MarketBeat
- Ocular Therapeutix (OCUL) Stock Trades Down, Here Is Why [Yahoo! Finance]Yahoo! Finance
- Ocular Therapeutix™ to Participate in March Investor ConferencesGlobeNewswire
- Ocular Therapeutix™ to Present Detailed SOL-1 Data at the 49th Macula Society Annual Meeting and Host Investor Webcast to Discuss PresentationsGlobeNewswire
OCUL
Earnings
- 11/4/25 - Beat
OCUL
Sec Filings
- 2/27/26 - Form 8-K
- 2/25/26 - Form 4
- 2/25/26 - Form 4
- OCUL's page on the SEC website